Compare General Motors Company (GM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Recursion Pharmaceuticals Inc — how do they compare? General Motors Company trades at $82.28 (market cap $72.17B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: General Motors Company is far larger — about 33.7× Recursion Pharmaceuticals Inc's market cap, and General Motors Company pays a 0.88% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GM | RXRX | |
|---|---|---|
Market Cap | $72.17B | $2.14B |
Volume | 4,900,304 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $6.79 |
52-Week Low | $55.35 | $2.84 |
Typical Hold Time | 83 Days | 22 Days |
Enterprise Value | $175.15B | $1.66B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.34, up 1.67% with recent earnings beats but faces bearish technical signals. The company reported declining Q3 2026 vehicle sales of 5.5% amid EV market challenges, while maintaining strong cash flow from operations at $26.87B in 2025. Valuation metrics show a P/E of 36.72 and P/S of 0.42, with analyst consensus favoring a Buy rating and $102.08 price target.
GM's outlook is mixed with solid fundamentals offset by near-term headwinds. Investment opportunities include potential regulatory savings of $20.4B from eased fuel economy rules and consistent earnings outperformance. Key risks involve competitive pressure from Asian automakers, declining market share, and profitability pressures with net margins at 1.05%.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
